机译:在丹麦和瑞典常规护理中常规护理中的类风湿性关节炎患者严重感染风险
DANBIO and Copenhagen Center for Arthritis Research (COPECARE) Center for Rheumatology and Spine;
Department of Medicine Solna Karolinska Institutet Stockholm Sweden;
DANBIO and Copenhagen Center for Arthritis Research (COPECARE) Center for Rheumatology and Spine;
Department of Clinical Epidemiology Aarhus University Hospital Aarhus Denmark;
DANBIO and Copenhagen Center for Arthritis Research (COPECARE) Center for Rheumatology and Spine;
Departments of Clinical Medicine and Rheumatology Aalborg University and Aalborg University;
Department of Clinical Epidemiology Aarhus University Hospital Aarhus Denmark;
ZiteLab ApS Copenhagen Denmark;
Department of Medicine Solna Karolinska Institutet Stockholm Sweden;
DANBIO and Copenhagen Center for Arthritis Research (COPECARE) Center for Rheumatology and Spine;
rheumatoid Arthritis; infections; DMARDs (biologic); treatment; epidemiology;
机译:在丹麦和瑞典常规护理中常规护理中的类风湿性关节炎患者严重感染风险
机译:EuroQol-5量度根据英国和瑞典对使用阿巴西普,利妥昔单抗,托珠单抗或肿瘤坏死因子抑制剂治疗的类风湿性关节炎的喜好设定:一项来自瑞典南部的前瞻性队列研究
机译:在常规护理中治疗的类风湿性关节炎患者患者中Certolizumab Pegol,Abatacep和BioSimilar infliximab的比较有效性:丹麦丹比奥丹比奥登记处的观测数据模仿随机试验
机译:生物CTLA4Lg(Abatacept)减少了类风湿性关节炎(RA)中的CD28〜(零)T细胞
机译:抵抗训练对接受线虫治疗的类风湿关节炎患者胰岛素敏感性和炎症标志物的影响。
机译:根据英国和瑞典的偏爱EuroQol-5的效用增益取决于使用阿巴西普利妥昔单抗托珠单抗或肿瘤坏死因子抑制剂治疗的类风湿性关节炎:一项来自瑞典南部的前瞻性队列研究
机译:根据英国和瑞典的偏爱,EuroQol-5的效用增益取决于使用阿巴西普,利妥昔单抗,托珠单抗或肿瘤坏死因子抑制剂治疗的类风湿性关节炎:一项来自瑞典南部的前瞻性队列研究